Breast Cancer Family Registry Cohort

乳腺癌家族登记队列

• 批准号: 10180905
• 负责人: Irene Andrulis
• 金额: $ 200万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-12 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10180905
• 关键词: Address; Affect; Age; Australia; BRCA1 gene; BRCA2 gene; Behavioral; Big Data; Blood; Blood specimen; Breast; Breast Cancer Risk Factor; Canada; Cancer Etiology; Cell Line; Cessation of life; Characteristics; Chemoprevention; Clinical; Collaborations; Collection; Communities; Complement; Complex; DNA; Data; Data Collection; Data Linkages; Data Set; Databases; Death Records; Development; Diagnosis; Early identification; Enrollment; Environmental Exposure; Etiology; Event; Family; Family member; Family-Based Registry; Gene Mutation; Generations; Genetic Predisposition to Disease; Genetic Risk; Genomics; Genotype; Germ-Line Mutation; Goals; Health behavior; Hereditary Breast Carcinoma; Hormones; Incidence; Individual; Infrastructure; International; Intervention; Investigation; Knowledge; Length; Life; Life Cycle Stages; Life Style; Malignant Neoplasms; Mammary Gland Parenchyma; Mammographic Density; Mammography; Measurement; Measures; Menstrual cycle; Methods; Modeling; Molecular; Newly Diagnosed; Operative Surgical Procedures; Optics; Outcome; Participant; Pathologic; Physical activity; Plasma; Positioning Attribute; Predisposition; Pregnancy; Prevention; Prevention Research; Primary Prevention; Questionnaires; Radiation; Recording of previous events; Registries; Reproductive History; Research; Resources; Risk; Risk Assessment; Risk Factors; Role; Scientist; Second Primary Cancers; Secondary Prevention; Site; Spectrum Analysis; Techniques; Technology; Testing; Tissue Banks; Tissue Sample; Translational Research; Tumor Tissue; Update; Woman; Women' s Health; aged; base; breast cancer diagnosis; breast cancer family registry; cancer epidemiology; cancer risk; clinical risk; cohort; data repository; design; digital; digital imaging; early detection biomarkers; emerging adult; ethnic diversity; follow-up; genetic discrimination; genetic variant; genomic data; improved; intervention program; malignant breast neoplasm; member; men; mobile application; mortality; multiple omics; new technology; novel; novel strategies; prospective; psychosocial; public health research; racial diversity; recruit; risk perception; risk prediction model; screening; screening guidelines; survivorship; targeted treatment; tertiary prevention; whole genome; young adult; young woman

The Breast Cancer Family Registry (BCFR) Cohort is a large and well-characterized international cohort of multi-generational families that has been created for interdisciplinary collaborative research. Established in 1995 at six sites across the US, Canada and Australia, we recruited and followed 40,029 individuals (33,037 women and 6,992 men) from 15,056 families across the full spectrum of familial risk and/or genetic predisposition. Through recruitment of multiple family members across generations, the BCFR Cohort is unique from other cohorts of unrelated individuals, and has a wide range of absolute breast cancer risk, which enables investigation of factors that modify breast cancer susceptibility and outcomes after diagnosis across the spectrum of risk. The BCFR Cohort is also unique for its comprehensive biospecimen resources, including cell lines for many participants complementing standard stored DNA, plasma and tissue samples. We have followed individuals who were unaffected (n=27,671) and affected (n=12,358) with breast cancer at baseline for up to 25 years (average length of follow-up = 15.2 and 16.1 years, respectively) and prospectively ascertained 879 incident breast cancers and 863 second breast events, respectively. The overarching goal of this application is to enrich the BCFR Cohort by building upon and enhancing the core infrastructure using long-term prospective data collection and measurement of key markers to address novel hypotheses in cancer etiology, survival and survivorship. We aim to answer questions on the role of life course accumulation of risk, critical windows of exposure, and the factors underling the increase in breast cancer incidence in young women. We propose to continue a systematic and coordinated approach across all six sites over the next five years to: 1) enhance the BCFR Cohort by enrolling young women aged 18–39 years who are relatives of enrolled family members and collecting detailed data on menstrual cycles, hormone exposure and physical activity using mobile app technology; 2) retain and follow currently enrolled members of the BCFR Cohort through another wave of follow-up questionnaires, and linkages to cancer and death registries; 3) create a big data repository of multiple “omics” datasets (e.g., whole genome, serial digital mammograms); and 4) expand the biospecimen resources, including collection of tissue and repeat blood samples. These activities will include collection and updating of detailed risk factor, biospecimen, clinical, and outcome data through novel approaches and technology (e.g., mobile app technologies, optical spectroscopy) and big data approaches. With the addition of these components, we will continue to provide the research community an important and unique family cohort to address cutting-edge research questions of clinical importance on cancer susceptibility, survival and survivorship (e.g., risk assessment, identification of early detection markers, knowledge and perception of risk). Through this resource, we envision a large platform for translational research that will provide rigorous evidence on complex questions related to primary, secondary and tertiary prevention efforts.

乳腺癌家族登记（BCFR）队列是一个大型且特征良好的国际队列， 为跨学科合作研究而创建的多代家庭。年成立 1995年，我们在美国、加拿大和澳大利亚的六个地点招募并跟踪了40，029名个体（33，037 女性和6，992名男性），来自15，056个家庭，涉及所有家族风险和/或遗传风险。 易感性通过招募多代家庭成员，BCFR队列是 与其他无关个体的队列相比是独特的，并且具有广泛的绝对乳腺癌风险， 能够调查改变乳腺癌易感性和诊断后结果的因素， 风险的范围。BCFR队列也因其全面的生物标本资源而独一无二，包括 许多参与者的细胞系补充了标准储存的DNA、血浆和组织样本。我们有 随访了基线时未受影响（n= 27，671）和受影响（n= 12，358）的乳腺癌患者 长达25年（平均随访时间分别为15.2年和16.1年）和前瞻性 分别确定了879例乳腺癌事件和863例第二乳腺事件。的首要目标 该应用程序旨在通过构建和增强核心基础设施来丰富BCFR队列 长期前瞻性数据收集和关键标志物的测量，以解决癌症中的新假设 病因学、存活率和存活率。我们的目标是回答生命过程中风险积累的作用， 暴露的关键窗口，以及导致年轻人乳腺癌发病率增加的因素 妇女我们建议在今后五年内继续在所有六个地点采取系统和协调的办法 1）通过招募年龄在18-39岁之间的年轻女性来加强BCFR队列，这些女性是以下人群的亲属： 招募家庭成员，收集有关月经周期、激素暴露和身体状况的详细数据。 使用移动的应用程序技术的活动; 2）保留和随访BCFR队列的当前入组成员 通过另一波后续调查问卷，以及与癌症和死亡登记的联系; 3）创建一个大的 多个“组学”数据集的数据储存库（例如，全基因组，连续数字乳房X光检查）;和4）扩展 生物样本资源，包括组织和重复血液样本的采集。这些活动将 包括收集和更新详细危险因素、生物样本、临床和结果数据， 方法和技术（例如，移动的应用程序技术、光谱学）和大数据方法。 随着这些组件的增加，我们将继续为研究界提供一个重要的， 独特的家庭队列，以解决癌症易感性的临床重要性的前沿研究问题， 生存和生存（例如，风险评估、早期检测标志物的识别、知识和 风险认知）。通过这个资源，我们设想了一个大型的转化研究平台， 就与一级、二级和三级预防工作相关的复杂问题提供严格的证据。